Media Room
Fourth Quarter and Full Year 2024 Results
Fourth quarter and full year 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session.
Thursday January 30, 2025
15:00 - 16:30 CET (9:00am – 10:30am EST)
Press releases
January 22, 2025
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
January 13, 2025
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
Half Year 2024 Financial Report XBRL Package
Half Year 2024 Financial Report
Declaration of extra-financial performance 2023 (ESG Report)
Half Year 2023 Financial Report